That's in animals in 2022. We've seen pretty good pre-clinical data already, but it's results in IPF patients that we won't see til the middle of FY24 now.
It's that part of the phase I that I had really been looking forward to, now it's canceled.
Ann: AD-214 pathway to IPF efficacy studies, page-59
Add 1AD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(2.78%) |
Mkt cap ! $11.05M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.7¢ | $10.56K | 588.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 718710 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 560699 | 4 |
View Market Depth
| Last trade - 14.06pm 14/11/2024 (20 minute delay) ? |
| 1AD (ASX) Chart |